• Happify Health, a digital therapeutics company, has partnered with pharmaceutical company Zuellig Pharma to commercialize two of its prescription drug therapeutics (PDTs) in Asia. 

• Under this agreement, Happify’s PDT “Ensemble” and its prescription PDT for chronic insomnia will be initially launched in South Korea and Taiwan, followed by a launch in 11 countries including Indonesia, Singapore, Malaysia, Thailand, and Hong Kong. Ensemble is used to treat major depressive disorder and generalized anxiety disorder.   

<ul><li>This partnership follows the news of the company releasing its PDT Ensemble in July of 2021 and its announcement of raising USD 73 million in March that year . While Ensemble is not currently FDA-approved, the company is launching this product in Asia in order to gather real-world data to support the approval process.</ul>